Random anti-Müllerian hormone (AMH) is a predictor of ovarian response in women with elevated baseline early follicular follicle-stimulating hormone levels

• Published in: Fertility and sterility Vol. 95; no. 7; pp. 2369 - 2372
• Main Authors: Buyuk, Erkan, M.D, Seifer, David B., M.D, Younger, Joshua, M.D, Grazi, Richard V., M.D, Lieman, Harry, M.D
• Format: Journal Article
• Language: English
• Published: New York, NY Elsevier Inc 01.06.2011; Elsevier
• Subjects: Adult; animal ovaries; Anti-Mullerian Hormone - blood; Anti-Müllerian hormone; assisted reproductive technologies; Biological and medical sciences; Biomarkers - blood; blood serum; Chi-Square Distribution; diminished ovarian reserve; elevated FSH levels; Embryo Transfer; Female; Fertilization in Vitro; Follicle Stimulating Hormone, Human - blood; follicle-stimulating hormone; Follicular Phase - blood; Gynecology. Andrology. Obstetrics; Humans; Infertility, Female - blood; Infertility, Female - physiopathology; Infertility, Female - therapy; Internal Medicine; Medical sciences; Müllerian inhibiting substance; New York; Obstetrics and Gynecology; Oocyte Retrieval; oocytes; ovarian response; Ovulation - drug effects; Ovulation Induction; patients; Pregnancy; Pregnancy Rate; prognosis; Retrospective Studies; Time Factors; Treatment Outcome; Up-Regulation; women; New York; Anti-Müllerian hormone; ART; Müllerian inhibiting substance; diminished ovarian reserve; elevated FSH levels; ovarian response; Human; Hormone; Reserve; Gynecology; Obstetrics; Ovary; Mullerian duct; Female; Early; Predictive factor; Woman; Follicle stimulating hormone
• ISSN: 0015-0282; 1556-5653
• DOI: 10.1016/j.fertnstert.2011.03.071

Objective To investigate the utility of random anti-Müllerian hormone (AMH) in assessing ovarian response among women with diminished ovarian reserve (DOR) diagnosed by elevated early follicular-phase FSH levels. Design Retrospective study. Setting Academic and academically affiliated assisted reproductive technology (ART) programs. Patient(s) Seventy-three women undergoing ART with elevated early follicular FSH levels. Intervention(s) None. Main Outcome Measure(s) Number of oocytes retrieved during ART cycle, number of day 3 embryos, and cycle cancellation and clinical pregnancy rates. Result(s) Random AMH levels were strongly correlated with the number of oocytes retrieved during an ART cycle among women with elevated FSH (r = 0.55). Women with elevated FSH who had a random serum AMH level of 0.6 ng/mL or higher had twice the number of oocytes retrieved (11 ± 1.3 vs. 5.6 ± 0.6), a greater number of day 3 embryos (5.7 ± 0.9 vs. 3 ± 0.5), and approximately a third of the cycle cancellation rate (14% vs. 41%) compared with women with a random serum AMH below 0.6 ng/mL. The clinical pregnancy rate was also higher among women with a random serum AMH ≥0.6 ng/mL (28% vs. 14%), however, the difference was not statistically significant. Conclusion(s) A random serum AMH level is useful in setting expectations for ART prognosis in women with elevated early follicular-phase serum FSH levels.